Sexton biotechnologies to be acquired by biolife solutions

Indianapolis, aug. 9, 2021 /prnewswire/ -- sexton biotechnologies, a provider of novel manufacturing solutions for the cell and gene therapy (cgt) industry, today announced that it has entered into a definitive agreement whereby biolife solutions (nasdaq: blfs) will acquire all outstanding shares of the company in a deal worth a total value of $30 million. during the past two years, sexton has worked to provide end-to-end solutions for emerging cell and gene therapy manufacturers.
BLFS Ratings Summary
BLFS Quant Ranking